What is the clinical evidence from this study?

Study design: Review. Population: Viral infections. Intervention: Defective viral genomes (DVGs) and defective interfering particles (DIPs).

May 8, 2026Microbiology and Molecular Biology Reviews

Turning defects into defenses: the potential and challenges of defective viral genome-based antiviral strategies

View Full Paper

Ask AI

Bookmark

Key result

Defective interfering particles show broad-spectrum antiviral promise by blocking viral replication and stimulating innate immunity.

Why the study?

Critical challenges remain for defective interfering particles and defective viral genomes to progress from promising preclinical agents to effective clinical antivirals.

Design

Review

Authors

DLDongsheng LiQIMR Berghofer Medical Research Institute MLMin‐Hsuan LinQIMR Berghofer Medical Research Institute HHHongyun HaoTongji University

Discussion

Member takes

Implication

Requires awareness of DIPs in RNA virus dynamics and outcomes; leaves open their therapeutic potential pending targeted trials.

Key Points

This review aims to evaluate the potential of defective viral genomes (DVGs) and defective interfering particles (DIPs) as antiviral strategies against RNA viruses.
Reviewed literature on DIPs and DVGs in positive- and negative-strand RNA viruses.
Analyzed the dual mechanisms of DVGs, focusing on their roles in viral replication interference and immune modulation.
Identified challenges in translating these strategies from preclinical research to clinical applications.
DIPs exhibit dual mechanisms: direct interference in viral replication and activation of innate immunity.
Therapeutic engineering of DIPs shows promise for broad-spectrum antiviral effects.
Challenges include understanding DVG formation and ensuring effective clinical application.

Structured PICO

Population

Positive- and negative-strand RNA viruses

Intervention

Defective interfering particles (DIPs) containing defective viral genomes (DVGs)

Defective viral genomes offer a versatile antiviral strategy through direct replication interference and robust immune activation.

Limitations

Critical remaining challenges for DIPs/DVGs to progress from promising preclinical agents to effective clinical antivirals

Cite This Study

Li et al. (2026) conducted a review in Viral infections. Defective viral genomes (DVGs) and defective interfering particles (DIPs) was evaluated. Defective viral genomes and defective interfering particles show promise as broad-spectrum antivirals by directly interfering with viral replication and potently stimulating innate immunity.

synapsesocial.com/papers/69fd7ec6bfa21ec5bbf07046 https://doi.org/10.1128/mmbr.00090-25

View Full Paper

Ask AI

Bookmark

Turning defects into defenses: the potential and challenges of defective viral genome-based antiviral strategies

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Turning defects into defenses: the potential and challenges of defective viral genome-based antiviral strategies

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider